Antofine suppresses endotoxin-induced inflammation and metabolic disorder via AMP-activated protein kinase

Shao-Ting Chou¹, Fang Jung², Shih-Hsing Yang³, Hwei-Ling Chou⁴, Guey-Mei Jow³ & Jau-Chen Lin²

¹Division of Chest Medicine, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan
²Department of Respiratory Therapy, Fu-Jen Catholic University, New Taipei City, Taiwan
³School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan
⁴Medical Department, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan

Keywords
AMPK, Antofine, endotoxin, inflammation, metabolism

Correspondence
Jau-Chen Lin, Department of Respiratory Therapy, Fu-Jen Catholic University, No.510, Zhongzheng Rd., Xinzhuang Dist., New Taipei City 24205, Taiwan. Tel: +886 2 2905 3795; Fax: +886 2 2905 2044; E-mail: 080659@mail.fju.edu.tw

Funding Information
This work was supported by the National Science Council of Taiwan [grants NSC101-2320-B-030-008-MY3].

Received: 18 December 2016; Revised: 20 May 2017; Accepted: 9 June 2017

Pharma Res Per, 5(4), 2017, e00337, https://doi.org/10.1002/prp2.337

doi: 10.1002/prp2.337

Abstract
The inhibition of activated macrophages has been used to develop anti-inflammatory agents for therapeutic intervention to human diseases that cause excessive inflammatory responses. Antofine, a phenanthroindolizidine alkaloid, has a potent anti-inflammatory effect. However, the molecular mechanisms of its anti-inflammatory activity have not yet been fully detailed. In this study, we comprehensively explored the anti-inflammatory effects of antofine on endotoxin-induced inflammation in macrophages using cDNA microarray analysis, thereby elucidating the potential mechanism by which antofine suppresses inflammation. Antofine significantly suppressed the secretion of proinflammatory cytokines such as TNFα and IL-1β and the production of iNOS in LPS-activated Raw264.7 macrophage cells. In addition, antofine can suppress the expressions of several inflammation-related genes (such as ARG-1, IL1F9, IL-10, and IL-33) and extracellular matrix genes (such as TNC and HYAL1), as well as a vasopressor gene (EDN1) in activated macrophage cells, that are induced by LPS stimulation. The gene expression profiles analyzed by GeneMANIA software showed that antofine not only contributed anti-inflammatory activity but also modulated the cellular metabolism via AMPK. Furthermore, antofine also modulated the activation of AMPK and caspase-1, the key regulator in inflammasome-mediated IL-1β maturation, in activated macrophage cells. In conclusion, these data indicated that antofine potentially can not only contribute an anti-inflammatory effect but can also attenuate the metabolic disorders induced by inflammation via AMPK.

Abbreviations
AMPK, AMP-activated protein kinase; ARG-1, arginase 1; EDN1, Endothelin 1; HYAL1, Hyaluronoglucosaminidase 1; IL-10, interleukin 10; IL1F9, interleukin-1 family member 9; IL-1, interleukin-1; IL-33, interleukin 33; iNOS, inducible nitric oxide synthase; LPL, lipoprotein lipase; LPS, Lipopolysaccharide; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; PCR, polymerase chain reaction; PGEs, prostaglandins; ROS, reactive oxygen species; SIRS, systemic inflammatory response syndrome; TNC, Tenascin C; TNFα, tumor necrosis factor-α.

Introduction
Endotoxin-induced acute and excessive inflammatory responses in patients including endotoxemia and systemic inflammatory response syndrome (SIRS) still cause high mortality despite advanced supportive care and clinical therapeutic intervention (Cohen 2002). Lipopolysaccharide (LPS), a bacterial endotoxin, can stimulate the acute
release of cytokines such as tumor necrosis factor-\(\alpha\) (TNF\(\alpha\)) to mediate the damage caused by inflammation (Tracey et al. 1986, 1987). TNF\(\alpha\) can enlarge and extend the inflammatory response by stimulating cells to secrete other cytokines including interleukin-1 (IL-1) and mediators such as prostaglandins (PGEs), nitric oxide, and reactive oxygen species (ROS), which amplify inflammation and cause tissue injury (Bradley 2008; Dinarello 2011). The immune cells, including macrophages and neutrophils, are thought to play a critical role in human immune responses to bacterial infections during the process of endotoxemia. Relatedly, the inhibition of activated macrophages has been used to develop potential anti-inflammatory compounds attenuating human diseases due to excessive inflammatory responses.

Antofine, a phenanthroindolizidine alkaloid, has previously been shown to exhibit antiviral (Gao et al. 2012; Wang et al. 2012) and antitumorigenic activities (Staerk et al. 2002; Fu et al. 2007), including suppressive effects on pancreatic cancer cells, by inhibiting the activation of NF-\(\kappa\)B (Shiah et al. 2006). Recently, it has also been reported that antofine can also exert potent anti-inflammatory effects, by suppressing the production of nitrite oxide induced by LPS challenge in murine macrophage cells (Min et al. 2010), and antiadipogenic effects via the direct suppression of PPAR\(\gamma\); protein expression in adipocyte cells (Jang et al. 2014). However, the details of the mechanism by which antofine exerts these anti-inflammatory and antiadipogenic effects remain unclear.

AMP-activated protein kinase (AMPK) is an important regulator of whole-body energy metabolism that mediates energy homeostasis including carbohydrate, lipid, and protein metabolism. However, dysregulation of AMPK causes obesity, metabolic syndrome, cardiovascular disease, and cancer (Steinberg and Kemp 2009). Several studies have shown that reduced AMPK activity is correlated with inflammation in adipose tissue and macrophages (Yang et al. 2010; Gauthier et al. 2011). The activation of AMPK activity by AICAR, an activator of AMPK, can inhibit LPS-induced inflammatory responses in an in vitro model, as well as the inflammation resulting from cystic fibrosis and lung injury in several animal models (Zhao et al. 2008; Myerburg et al. 2010). In this study, we comprehensively explored the anti-inflammatory effect of antofine on LPS-induced inflammation in macrophages using cDNA microarray analysis. We found that antofine not only contributes an anti-inflammatory effect but also an antifibrogenic effect, which together cause the suppression of the formation of extracellular matrix. In addition, this is the first study to identify the crosstalk between antofine and the activation of AMPK activity, which can suppress the inflammatory response in macrophages.

---

**Materials and Methods**

**Cell culture**

The cells including Raw264.7 murine macrophage and human bronchial epithelial (BEAS-2B) both were gotten from BCRC (Bioresource Collection and Research Center, Hsinchu, Taiwan). The cells were grown in normal DMEM (HyClone, Logan, UT) supplemented with 1.5 g/L of NaHCO3, 4.5 g/L glucose, as well as 10% fetal bovine serum (FBS, HyClone), MEM nonessential amino acid (Hyclone), 100 mM sodium pyruvate (Hyclone), and antibiotics (Hyclone).

**Chemicals**

The tested antofine (Fig. 1A, PubCnem CID 639288) was produced by Dr. KH Lee’s laboratory (Dong et al. 1999; Liu et al. 1999). LPS (Escherichia Coli 0111:B4) was purchased from Sigma-Aldrich (Saint Louis, MO).

**cDNA microarray**

Total RNA was extracted and isolated from the cells incubated with/without the lipopolysaccharide (1 \(\mu\)g/mL LPS; Escherichia Coli 0111:B4) alone or incubated with LPS plus antofine (10 ng/mL) for 24 h using TRIzol (Invitrogen). Five microgram of total RNA from each sample was performed in each cDNA microarray. Antisense RNA (aRNA) target was labeled using Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion Inc., Aus- tin, TX). Cy5-labeled RNA targets were hybridized to Mouse Whole Genome OneArray v2 (Phalanx Biotech Group), and the signal of hybridized spots in chip were detected by the Axon 4000 scanner (Molecular Devices). The intensity of each spot was analyzed by Genepix 4.1 software (Molecular Devices) (Lin et al. 2009; Morales et al. 2014). The microarray experiments were adhered to the guidelines of the Microarray Gene Expression Data Society (www.mged.org/Work groups/MIAME/miame_checklist.html).

**Real-time reverse transcriptase polymerase chain reaction**

Total RNA was extracted from the cultured cells using TRIZol reagent (Invitrogen), and then quantified using an Epoch Microplate Spectrophotometer with a Take3 Micro-Volume Plate (BioTek, Winooski, VT). One microgram of total RNA was reverse-transcribed using an MMLV reverse transcriptase kit with random primers (Epicentre Biotechnologies, Madison, WI). The specific primers for real-time quantitative PCR were designed by qPrimerDepot (http://primerdepot.nci.nih.gov/) (Table 1).
The real-time PCR reactions were performed in 20 μL volumes containing 10 μL of Real-time PCR DyNAmo Flash SYBR Green qPCR reagent (Thermo Fisher Scientific Inc., NYSE: TMO). The PCR reaction was performed using a PikoReal™ 96 Real-Time PCR System (Thermo Fisher Scientific Inc.), and the conditions were
as follows: 45 cycles of 95°C for 5 sec and 60°C for 1 min. The data were analyzed using PiKoReal Software 2.0, exported into Excel for analysis using the \( \Delta C_t \) (the number of PCR cycles to reach the threshold of the product detection) method, and normalized to \( \beta \)-actin as an internal control. The quantitative real-time PCR experiments adhered to the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines (http://www.clinchem.org/cgi/content/short/55/4/611).

### Enzyme-linked immunosorbent assay

The concentrations of TNF\( \alpha \) and IL-1\( \beta \) in cultured medium were examined by ELISA kit (eBioscience, San Diego, CA) according to the manufacturer’s instructions. The tested plates were analyzed at 450 nmol/L using an Epoch Microplate Spectrophotometer. The concentrations of TNF\( \alpha \) and IL-1\( \beta \) were calculated from the standard curve.

### Western blot analysis

Equal amounts of soluble protein extracted from cells were separated by SDS-PAGE and then transferred to a PVDF membrane (HybondTM-P, Amersham, Piscataway, NJ). The blots were probed with specific antibodies to iNOS (BD transduction Lab., San Jose, CA), EDN1, HYAL-1, ARG-1 (GeneTex, Inc., Irvine, CA), Caspase-1 (Millipore, Billerica, MA), IL-1\( \beta \) (Abnova, Taipei City, Taiwan), TNF\( \alpha \) (R&D Systems, Inc., Minneapolis, MN), p-A-CoA, p-AMPK\( \alpha \), and (Cell Signaling, Beverly, MA), and \( \beta \)-actin (Sigma-Aldrich). The signal of electrochemical luminescence in probed blots was detected using FUJI Medical X-ray film (FUJI Corporation, Kofu, Yamanashi, Japan). The densitometry of specific bands on the blot was measured by Image J software (NCBI).

### Cell viability assay

Cells were seeded at 10\(^5\) cells/well in each 96-well plates. The cells were treated with antofine (0–50 ng/mL) in 0.2 mL of culture medium for 48 h. 20 \( \mu \)L of WST-1 (Roche) was added to each well and incubated at 37°C for 2 h. The absorbance of the samples was measured at 450 nm wavelength using a spectrophotometer (BioTek Instruments, Inc.).

### Statistical methods

The quantitative data are expressed as means ± SD. Statistical significant of difference between groups was analyzed using the \( t \)-test. \( P < 0.05 \) were considered to be significant.
Results

A cell viability assay was performed to elucidate whether or not the suppressive effect on the production of inflammation-related genes was due to cell death, and the results showed that antofine exhibited no cell cytotoxicity in Raw264.7 macrophage cells at doses below 10 ng/mL but dramatically suppressed cell proliferation at a dose of 50 ng/mL (Fig. 1B). To evaluate the potential mechanism of antofine in inhibiting inflammation, Raw264.7 macrophage cells cotreated with LPS and antofine were harvested at 6-h and 24-h time points, and the total protein and RNA extracted from cells were analyzed using Western blotting and real-time PCR, respectively. The Western blotting results showed that the production of iNOS proteins was dramatically induced by LPS stimulation at 24 h but was decreased in a dose-dependent manner as the dose of antofine compound was increased (Fig. 1C). The real-time PCR results also confirmed that the suppressive effect of antofine on the expression of the iNOS gene was due to the modulation of gene transcription (Fig. 1D). The Western blot results showed that the antofine dose dependently inhibited the production of full length TNFα induced by LPS stimulation at the 6-h time point. However, the production of TNFα was no change in LPS-treated cells at the 24-h time point because the cells have been desensitized to LPS stimulation (Fig. 1E). The ELISA results also showed that secretion of TNFα (soluble form) in LPS-stimulated macrophage cells were dramatically suppressed at the 6-h time point. The increase secretion of TNFα in culture medium at the 24-h time point when compared with 6-h time point was due to accumulation of soluble TNFα for 24 h (Fig. 1F).

To elucidate the molecular mechanism by which antofine suppresses the LPS-induced inflammation of cells, we used a cDNA microarray with free software tools from the Genemania and Panther web sites to analyze the changes in gene expression after cells were exposed to LPS (1 µg/mL) with or without antofine (10 ng/mL). In total, 854 putative genes showed a statistically significant fourfold difference in expression in Raw264.7 cells after 24 h of LPS stimulation compared with untreated control cells. Of these 854 genes, 348 were upregulated and 506 were downregulated (Fig. 2A and B). The upregulated genes are those involved in responses to stimuli, as well as metabolic, cellular, development, and immune system processes. In contrast, biological regulation, metabolic process, and localization process genes were downregulated significantly by treatment with LPS. 115 of the 348 genes induced by LPS were suppressed by antofine treatment (Fig. 2C). Seventy-six of the 506 genes downregulated by LPS were enhanced by antofine treatment (Fig. 2D). Interestingly, 48 (63.2%) of these 76 enhanced genes were involved in metabolic processes. This result indicated that antofine may reactivate metabolic pathways to suppress LPS-induced inflammatory responses.

In order to confirm the effects of antofine on the expression of inflammatory mediators, the mRNA or proteins of several inflammatory mediators were detected either by quantitative RT-PCR or Western blotting, respectively. As shown in Table 2, the upregulated genes were enhanced by LPS at least threefold higher than they were in the untreated control cells (column 2), and they were suppressed by LPS plus antofine cotreatment, the effects of which were analyzed by cDNA array data (column 3). The fold changes in the expression levels of these genes (column 5, 6) in LPS alone or LPS plus antofine cotreated cells compared to control cells were detected and determined by real-time PCR with specific designed primers (Table 1). To further verify the real-time PCR results, Raw264.7 macrophage cells were pretreated with various concentrations of antofine for 30 min and then stimulated by LPS for 24 h, and the total protein and RNA extracted from the cotreated cells were analyzed using Western blotting and RT-PCR, respectively. The results showed that the expressions of inflammatory cytokines (such as IL1F9, IL-10, and IL-33) and extracellular matrix genes (such as TNC and HYAL1), as well as that of a vasopressor gene (EDN1), were dose dependently downregulated by antofine treatment according the results of the real-time PCR (Fig. 3A). The Western blots also confirmed that protein concentrations of LPS-induced genes including HYAL-1, EDN1, and ARG-1 were dose dependently suppressed by antofine treatment (Fig. 3B).

To further clarify the potential mechanism of the anti-inflammatory effects of antofine on LPS-induced activation of Raw264.7 murine macrophage cells, we analyzed the 48 genes that were downregulated by LPS stimulation but reactivated by antofine treatment in macrophage cells. The results, which were analyzed using the GeneMANIA database, showed that six genes, namely, WDR36, LPL, PPP2R3C, PA2G4, HNRPU, and CAD, contributed physical interactions with PRKAA1 (AMPK) (Fig. 4). In addition, the results indicated that MAT2A has a genetic interaction with AMPK, whereas DYRK3 shares a protein domain with AMPK. These results further indicate that AMPK may play an important role in suppressing LPS-induced inflammation in Raw264.7 macrophage cells.

To confirm whether or not AMPK was involved in the modulation of LPS-induced inflammation by antofine, we assayed the AMPK signaling pathway by Western blot with specific antibodies. The results showed that the AMPKα was activated by antofine and an AMPKα downstream targeted protein, acetyl-CoA carboxylase, was significantly dose-dependently inactivated (with
Antofine Suppresses Inflammation via AMPK

(A) LPS activates the expression of 348 genes

- Response to stimulus (GO:0050896) 100 28.7% 12.1%
- Metabolic process (GO:0008152) 165 47.4% 19.9%
- Cellular process (GO:0009987) 174 50.0% 21.0%
- Developmental process (GO:0032502) 74 21.3% 8.9%
- Immune system process (GO:0002376) 91 26.1% 11.0%

(B) LPS suppresses the expression of 506 genes

- Biological regulation (GO:0065007) 70 13.8% 9.4%
- Metabolic process (GO:0008152) 276 54.5% 36.9%
- Cellular process (GO:0009987) 164 32.4% 21.9%
- Developmental process (GO:0032502) 50 9.9% 6.7%
- Localization (GO:0051179) 53 10.5% 7.1%

(C) Antofine attenuate the expression of LPS-induced 115 genes

- Response to stimulus (GO:0050896) 28 24.3% 11.0%
- Metabolic process (GO:0008152) 47 40.9% 18.5%
- Cellular process (GO:0009987) 61 53.0% 24.0%
- Developmental process (GO:0032502) 21 18.3% 8.3%
- Immune system process (GO:0002376) 23 20.0% 9.1%

(D) Antofine enhances the expression of LPS-suppressed 76 genes

- Biological regulation (GO:0065007) 8 10.5% 8.2%
- Metabolic process (GO:0008152) 48 63.2% 49.5%
- Cellular process (GO:0009987) 16 21.1% 16.5%
- Developmental process (GO:0032502) 3 3.9% 3.1%
- Localization (GO:0051179) 9 11.8% 9.3%
phosphorylation leading to the inactivation of this enzyme) by antofine (Fig. 5A). Conversely, antofine dose dependently suppressed the production of iNOS and the phosphorylation of AMPK, both induced by LPS at the 6-h and 24-h time points (Fig. 5B). The AMPK activator, AICAR, was able to activate AMPKζ but also suppressed the production of iNOS in LPS-treated macrophage cells. Interestingly, another AMPK activator, metformin, does not suppress the production of iNOS in LPS-treated macrophage cells. In Figure 5G, the results showed that the production of TNFζ was associated with the activation of AMPKζ. Antofine can suppress AMPK activities enhanced by AICAR and suppress the production of TNFζ. However, the cotreatment of antofine and compound C, AMPK inhibitor, can synergistically suppress the activation of AMKPζ as well as the production of TNFζ. It indicated that antofine inhibited the production of TNFζ via suppressing the activation of AMPK induced by LPS stimulation.

The secretion of IL-1β was low, it exhibited no significant changes at 6 h but was dramatically induced at 24 h (when compared with the LPS-unstimulated cells) and dose dependently decreased when antofine was coincubated at the 24-h time point (Fig. 6A). The Western blot results showed that the production of pro-IL-1β was enhanced by LPS stimulation and dose dependently suppressed by antofine treatment at the 6-h time point. However, the soluble form of IL-1β was absent in the

| Symbol | cDNA Microarray, fold change (mean ± SD) | Real-time PCR, fold change (mean ± SD) |
|--------|----------------------------------------|-----------------------------------------|
|        | LPS alone /control | LPS + Antofine /control | Molecular function | LPS alone /control | LPS + Antofine /control |
| IL33   | 3375.1 ± 96.7 | 1620.4 ± 133.5 | Cytokine | 284878 ± 33433 | 77303 ± 26370 |
| IL7R   | 42.8 ± 1.7    | 18.8 ± 1.8       | Receptor activity | 188.5 ± 35.8 | 38.7 ± 8.5 |
| IL10   | 9.6 ± 1.9     | 3.0 ± 0.0        | Cytokine | 1258.2 ± 941.8 | 138.1 ± 1.4 |
| ARG1   | 88.0 ± 0.5    | 7.8 ± 0.6        | Hydrolase activity | 1064.6 ± 411.9 | 101.3 ± 19.3 |
| TNC    | 8.6 ± 0.6     | 2.4 ± 0.3        | Receptor binding | 233.5 ± 33.1 | 20.9 ± 5.9 |
| ALDH1B1| 6.8 ± 0.2     | 2.5 ± 0.1        | Oxidoreductase activity | 11.1 ± 3.9 | 3.1 ± 0.3 |
| CTH    | 14.2 ± 1.1    | 3.1 ± 0.3        | Lyase activity | 12.4 ± 2.8 | 1.5 ± 0.4 |
| MYC    | 17.3 ± 1.4    | 8.9 ± 0.5        | Transcription factor | 15.4 ± 4.3 | 4.0 ± 0.4 |
| F7     | 3.0 ± 0.1     | 0.4 ± 0.2        | Calcium ion binding | 29.1 ± 1.7 | 3.3 ± 0.7 |
| SRC    | 8.1 ± 0.4     | 3.7 ± 0.8        | Tyrosine kinase activity | 44.8 ± 1.8 | 29.1 ± 0.3 |
| IFNB1  | 4.7 ± 0.5     | 1.6 ± 0.1        | Cytokine receptor binding | 26.7 ± 0.8 | 2.7 ± 0.9 |
| PECAM1 | 2.3 ± 0.7     | 0.3 ± 0.1        | Receptor activity | 10.6 ± 0.2 | 2.8 ± 0.4 |
| CCR2   | 3.1 ± 0.3     | 1.1 ± 0.1        | Receptor activity | 6.6 ± 2.8 | 3.5 ± 1.1 |
| DDX4   | 2.9 ± 1.1     | 0.8 ± 0.2        | RNA helicase activity | 4.4 ± 0.6 | 0.3 ± 0.2 |
| HOX1   | 6.7 ± 0.1     | 4.3 ± 0.3        | Oxidoreductase activity | 11.0 ± 4.1 | 2.9 ± 1.5 |
| NDST1  | 3.8 ± 0.2     | 0.8 ± 0.1        | N-sulfotransferase | 17.1 ± 0.1 | 4.9 ± 1.7 |
| HYAL1  | 3.8 ± 0.1     | 0.5 ± 0.0        | Hydrolase activity | 2.4 ± 0.6 | 0.2 ± 0.1 |
| LAPTM4B| 4.8 ± 0.3     | 0.9 ± 0.2        | Transmembrane transporter | 3.4 ± 0.7 | 0.5 ± 0.1 |
| NPC1   | 3.3 ± 0.1     | 1.4 ± 0.1        | Receptor activity | 5.4 ± 1.1 | 1.4 ± 0.3 |

Affected Genes Related to Inflammation. The up-regulated genes were enhanced by LPS at least threefold higher than they were in the untreated control cells (column 2), and they were suppressed by LPS plus antofine cotreatment (column 3). Quantitative real-time PCR with specific designed primers (Table 1) was performed to detect the expression level of these genes in LPS alone or LPS plus antofine cotreatment (column 5, 6). The PCR reaction was performed using a PikoReal™ 96 Real-Time PCR System (Thermo Fisher Scientific Inc.), and the conditions were as follows: 45 cycles of 95°C for 5 sec and 60°C for 1 min. The data were analyzed using PikoReal Software 2.0, exported into Excel for analysis using the ΔΔCt (the number of PCR cycles to reach the threshold of the product detection) method, and normalized to β-actin as an internal control. Results were presented as means ± SD.

© 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
culture medium due to un-digested protein from pro-IL-1β at the 6-h time point. Interestingly, the protein of pro-IL-1β was dramatically digested and the soluble form of IL-1β were increased in LPS-stimulated cells at 24 h, but the digestive effect of pro-IL1β was dose dependently inhibited by antofine treatment (Fig. 6B). The protein of caspase-1, the key regulator in inflammasome mediating IL-1β maturation, was in-activated (decrease cleaved form...
of caspase-1) when the cells were cotreated with antofine in a dose-dependent manner (Fig. 6C). A similar phenomenon to that which occurred in the Raw264.7 macrophage cells was also observed in the human lung bronchial epithelial cells (Fig. 6D). These results indicated that antofine inhibits the activity of caspase-1 and the maturation of proinflammatory cytokines such as IL-1β.

In conclusion, antofine may suppress LPS-induced inflammatory responses and modulate metabolic process-related genes via AMPK, as shown in Figure 7, which is a schematic representation of the role of AMPK as a regulator of LPS-induced signaling pathways.

Discussion

In this study, we demonstrated that antofine significantly suppressed the secretion of proinflammatory cytokines such as TNFα and IL-1β and the production of iNOS in LPS-activated Raw264.7 cells. In addition, cDNA array analysis and subsequent experiments confirmed that several inflammation-related genes (such as ARG-1, IL1F9, IL-10, and IL-33) and extracellular matrix genes (such as TNC and HYAL1), as well as a vasopressor gene (EDN1), were induced by LPS stimulation and dose dependently downregulated by antofine treatment. We also
comprehensively analyzed the profiles of gene expression in Raw264.7 murine cells treated with LPS alone or cotreated with LPS and antofine using GeneMANIA software, and found that antofine not only contributes anti-inflammatory activity but also modulates the metabolism via AMPK. Furthermore, we also found that antofine modulates the activity of caspase-1, the key regulator in inflammasome mediating IL-1β maturation, in Raw264.7 cells. These data indicated that antofine potentially can not only contribute an anti-inflammatory effect but can also attenuate the metabolic disorders induced by inflammation via AMPK.

Figure 5. Antofine activated AMPK and suppressed LPS-induced AMPK activation and inflammation mediators. (A) Raw264.7 macrophage cells were treated with antofine at the indicated concentrations for 2 h. The phosphorylation of acetyl-CoA carboxylase and AMPK was examined by immunoblot. (B) Raw264.7 macrophage cells were pretreated with various compounds including antofine (5 and 10 ng/mL), AICAR (0.5 mmol/L) and Metformin (1 mmol/L) for 30 min and then stimulated by LPS (1 μg/mL) for 6 h and 24 h. The production of iNOS and the phosphorylation of acetyl-CoA carboxylase and AMPK were examined by immunoblot. (C) Raw264.7 macrophage cells were pretreated with various compounds as indicated such as antofine (10 ng/mL), AICAR (0.5 mmol/L) and Compound C (10 µmol/L) for 30 min and then stimulated by LPS (1 μg/mL) for 6 h. The production of TNFα as well as the phosphorylation of acetyl-CoA carboxylase and AMPK was examined by immunoblot. The expression of β-actin served as an internal control.
Our data showed that antofine can modulate the expression of lung fibrosis-related cytokines such as IL-10 and IL-33. IL-33, a member of the IL-1 family of cytokines that signals through the ST2 receptor, has recently been identified as a key regulator of inflammatory and immune processes. IL-33 expression has been found to be increased in several pathological conditions, such as in the lung epithelial cells of asthmatic patients (Prefontaine et al. 2010) and COPD patients (Byers et al. 2013). In addition, several recent studies have shown that elevated IL-33 also promotes the initiation and progression of lung fibrosis (Luzina et al. 2013; Li et al. 2014). IL-10 is known as an anti-inflammatory cytokine involved in the processing of immunosuppressive effects which are necessary for regulating inflammation. Sun et al. (2011) have demonstrated that IL-10 drives fibrocyte recruitment to the lung and promotes the development of lung fibrosis. Intriguingly, we found that IL-33 and IL-10 were both elevated by LPS stimulation and then suppressed by antofine treatment in macrophage cells. It seems that antofine can potentially inhibit lung inflammation as well as any subsequent lung fibrosis through the suppression of these profibrogenic cytokines induced by LPS stimulation. Furthermore, we also found that LPS-induced expressions of extracellular matrix genes such as TNC and HYAL1, as well as a vasopressor gene, EDN1, all of which are involved in the process of lung fibrosis, were also dose dependently downregulated by antofine treatment. Cumulative data suggest that antofine can not only suppress endotoxin-induced inflammation in macrophage cells but can also prevent subsequent tissue fibrosis through the downregulation of profibrogenic cytokines and related fibrogenic genes. However, this interesting hypothesis should be addressed in the future in animal models.

This study also showed that antofine can modulate the secretion of several proinflammatory cytokines such as IL-1β and TNFα, although it does not modulate the secretion of IL-6 (data not shown). Our data showed that
Antofine dose dependently suppressed the production and secretion of TNFα in the early phase of inflammation when exposed to LPS. The soluble form of IL-1β was digested from pro-IL-1β by caspase-1, which was activated in the late phase of inflammation. Therefore, this can explain why the secretion of IL-1β in the culture medium was low at 6 h but dramatically enhanced at 24 h when compared with the LPS-unstimulated cells (Fig. 6A). However, these results implied that antofine may modulate LPS-induced inflammation in macrophage cells via an intracellular signaling network. The results of cDNA microarray analysis further showed that antofine, under the optional window dosage (~10 ng/mL), can significantly restore the downregulated genes suppressed by LPS stimulation, a majority of which (63%, 48 of 76) are involved in the metabolic process. Interestingly, the results further indicated that PRKKA1 (AMPK) can interact with most of these metabolism-related genes restored by antofine (Fig. 4), and this phenomenon indicates that AMPK signaling may play an important role in the suppression of LPS-induced inflammation by antofine. Numerous studies have also reported that the activation of AMPK signaling downregulates the function of the NF-κB system via its downstream mediators, for example SIRT1, the FoxO family (Zhang et al. 2010; Salminen et al. 2011; Huang et al. 2015). Yang et al. (2010) revealed that the activation of α1AMPK can suppress NF-κB signaling and fatty acid-induced inflammation; conversely, the suppression of α1AMPK reverse this inhibition. Activation of AMPK by resveratrol inhibits LPS-induced activation of NF-κB and the expression of COX2 in macrophage cells (Yi et al. 2011). Interestingly, we found that antofine alone can activate AMPK activity, but it also suppresses the LPS-induced activation of AMPK in macrophage cells. However, the detailed mechanism of antofine regarding its counteracting of the activation of AMPK induced by LPS stimulation remains unknown. In addition, Jang et al. (2014) demonstrated that antofine can contribute antiangiogenic activity at low concentrations (0.01–10 nmol/L) via the suppression of the PPARγ gene in adipocytes. Our current data also showed that antofine can restore the expression of lipoprotein lipase (LPL) suppressed by LPS-induced inflammation. This finding indicated that antofine may be a promising candidate for controlling obesity and metabolic disorders.

Activation of inflammasome is involved in obesity-related diseases, such as type II diabetes, and in cardiovascular diseases (Martinon et al. 2009; Horng and Hotamisligil 2011; Wen et al. 2011). AMPK regulates inflammasomal activation by inhibiting NF-KB activation (Hattori et al. 2008). We also confirmed that antofine can suppress the activity of caspase-1 in Raw264.7 cells when cotreated with LPS. This means that antofine can modulate the activity of inflammasomes that are activated in obesity-related diseases. The data further indicated that antofine potentially can not only contribute an anti-inflammatory effect but can also attenuate the metabolic disorders induced by chronic inflammation via AMPK. However, the details of the mechanism by which this occurs will have to be determined by further research conducted with other animal models.

**Acknowledgements**

We thank Ms. Chia-Yu Hou, Mr. Siao-Syuan Jian (Respiratory Therapy) and Ms. Ming-Lu Wang (School of Medicine, Fu-Jen Catholic University, Taipei City, Taiwan) for performing some of the experiments.
Author Contribution
Shao-Ting Chou, Hwei-Ling Chou, and Jau-Chen Lin participated in research design. Fang Jung and Shih-Hsing Yang conducted the experiments. Fang Jung, Shih-Hsing Yang, and Jau-Chen Lin performed data analysis. Guey-Mei Jow and Jau-Chen Lin wrote or contributed to the writing of the manuscript.

Disclosure
None declared.

References
Bradley JR (2008). TNF-mediated inflammatory disease. J Pathol 214: 149–160.
Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. (2013). Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123: 3967–3982.
Cohen J (2002). The immunopathogenesis of sepsis. Nature 420: 885–891.
Dinarello CA (2011). A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 41: 1203–1217.
Dong G, Chen Z, Kato T, Van Waes C (1999). The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59: 3495–3504.
Fu Y, Lee SK, Min HY, Lee T, Lee J, Cheng M, et al. (2007). Synthesis and structure-activity studies of antofine analogues as potential anticancer agents. Bioorg Med Chem Lett 17: 97–100.
Gao S, Zhang R, Yu Z, Xi Z (2012). Antofine analogues can inhibit tobacco mosaic virus assembly through small-molecule-RNA interactions. ChemBioChem 13: 1622–1627.
Gauthier MS, O’Brien EL, Bigornia S, Mott M, Caccicedo JM, Xu XJ, et al. (2011). Decreased AMPK-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 404: 382–387.
Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K (2008). High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett 582: 1719–1724.
Horng T, Hotamisligil GS (2011). Linking the inflammasome to obesity-related disease. Nat Med 17: 164–165.
Huang BP, Lin CH, Chen HM, Lin JT, Cheng YF, Kao SH (2015). AMPK activation inhibits expression of proinflammatory mediators through downregulation of PI3K/p38 MAPK and NF-kappaB signaling in murine macrophages. DNA Cell Biol 34: 133–141.
Jang EJ, Kim HK, Jeong H, Lee YS, Jeong MG, Bae SJ, et al. (2014). Anti-adipogenic activity of the naturally occurring phenanthroindolizidine alkaloid antofine via direct suppression of PPARgamma expression. Chem Biodivers 11: 962–969.
Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, et al. (2014). IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134(1422–1432): e1411.
Lin JC, Yang SC, Hong TM, Yu SL, Shi Q, Wei L, et al. (2009). Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways. J Med Chem 52: 1903–1911.
Liu W, Li J, Roth RA (1999). Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun 261: 897–903.
Luzina IG, Kopach P, Lockatell V, Kang PH, Nagarsekar A, Burke AP, et al. (2013). Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 49: 999–1008.
Martinon F, Mayor A, Tschopp J (2009). The inflammasomes: guardians of the body. Annu Rev Immunol 27: 229–265.
Min HY, Song SH, Lee B, Kim S, Lee SK (2010). Inhibition of lipopolysaccharide-induced nitric oxide production by antofine and its analogues in RAW 264.7 macrophage cells. Chem Biodivers 7: 409–414.
Morales C, Rachidi S, Hong F, Sun S, Ouyang X, Wallace C, et al. (2014). Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res 74: 446–459.
Myerburg MM, King JD Jr, Oyster NM, Fitch AC, Magill A, Baty CJ, et al. (2010). AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 42: 676–684.
Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. (2010). Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 125: 752–754.
Salminen A, Hyttninen JM, Kaarmiranta K (2011). AMPK-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 89: 667–676.
Shiah HS, Gao W, Baker DC, Cheng YC (2006). Inhibition of cell growth and nuclear factor-kappaB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol Cancer Ther 5: 2484–2493.
Staerk D, Lykkeberg AK, Christensen J, Budnik BA, Abe F, Jaroszewski JW (2002). In vitro cytotoxic activity of
phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells. J Nat Prod 65: 1299–1302.

Steinberg GR, Kemp BE (2009). AMPK in Health and Disease. Physiol Rev 89: 1025–1078.

Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, et al. (2011). New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol 300: L341–L353.

Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Millsark JW, et al. (1986). Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474.

Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662–664.

Wang Z, Wei P, Xizhi X, Liu Y, Wang L, Wang Q (2012). Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives. J Agric Food Chem 60: 8544–8551.

Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. (2011). Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408–415.

Yang Z, Kahn BB, Shi H, Xue BZ (2010). Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285: 19051–19059.

Yi CO, Jeon BT, Shin HJ, Jeong EA, Chang KC, Lee JE, et al. (2011). Resveratrol activates AMPK and suppresses LPS-induced NF-kappaB-dependent COX-2 activation in RAW 264.7 macrophage cells. Anat Cell Biol 44: 194–203.

Zhang Z, Lowry SF, Guarente L, Haimovich B (2010). Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J Biol Chem 285: 41391–41401.

Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y, et al. (2008). Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295: L497–L504.